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Health care systems have considered the introduction of health technologies a linear process in
which different stakeholders (innovators, manufacturers, regulators, health technology assessors,
reimbursement bodies, health care providers, health care professionals, patients, and citizens) did
interact in each of the steps of the process, but were not involved in a continuous dialogue and
knowledge exchange. This step by step approach generates inefficiency in many cases by means of:
the isolation of innovators from real health care needs, the introduction of health technologies of
doubtful value, the generation of unnecessary variability in practice, the maintenance of practices
of no-added value, and the disregard of knowledge out of the practice, among others. These
circumstances suppose an inefficient allocation of resources and investment, a hole in the waterline
of health care systems, and their sustainability and what is more, a non-direct correlation between
expected or theoretical outcomes and real health outcomes. Different initiatives have been put in
place in the last years in order to mitigate the effects of the aforementioned issues.
On the basis of the life cycle concept of health technologies (see Figure 1), this article will go
through some of these initiatives and define the role that Health Technology Assessment could
play in each step.
Health Technology Assessment (HTA) is “the systematic evaluation of the properties and effects of
a health technology, addressing the direct and intended effects of this technology, as well as its indirect
and unintended consequences, and aimed mainly at informing decision making regarding health
technologies. HTA is conducted by interdisciplinary groups that use explicit analytical frameworks
drawing on a variety of methods” HTAglossary (http://htaglossary.net).
HTA was used to act when decisions on reimbursement were required and thus was called
the fourth hurdle or the fourth guarantee (safety, efficacy, effectiveness, and efficiency). However,
having in mind its definition and privileged position, HTA activities have evolved to more
constructive approaches from health technology inception to its obsolescence (Henshall et al.,
2011). New concepts such as scientific advice (Jost et al., 2015), early dialogue, early awareness, and
alert systems (Packer et al., 2012), post-introduction observation of health technologies (Varela-
Lema et al., 2012), appropriateness, re-assessment, and disinvestment (Elshaug et al., 2007) have
gained ground.
RESEARCH AND DEVELOPMENT
In the nineties of the 20th century, many countries in the world started policies on incentivizing
the creation of innovation hubs and enterprises incubators in different sectors, especially
energy, transport, and biosciences-health. These policies were followed by supporting innovators,
universities, spin-offs, spin-outs, and small and medium enterprises (SMEs) both managerially
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FIGURE 1 | The life cycle of health technologies concept. ELSOI (Ethical, Legal, Social and Organizational Issues).
and economically. These policies generated an increasing
amount of initiatives and technological ideas. One of the
challenges of those innovators were centered in convincing
the health care systems on the added-value of their ideas
and anticipating financial needs, especially regulators, and
reimbursement requirements of evidence generation. Regulatory
agencies including the European Medicines Agency (EMA)
established focused policies to promote innovative solutions and
especially the development of new drugs by SMEs. Furthermore,
EMA launched in 2005 an “SME Office” to provide financial and
administrative assistance to micro-SMEs (Carr, 2010).
Unfortunately, many of these initiatives failed, not linked
to their possible value to health systems, but rather due to
inadequate planning of the steps to be followed in the continuum
from regulation to market access. This misalignment between
innovators, regulators, and health care systems have generated
that many laboratory discoveries have gone to the termed
“valley of death,” the so-called gap between bench research
to health care application (Roberts et al., 2012). Moreover, as
Roberts et al. (2012) described there are fewer scientists with
a true understanding of clinical problems and health needs.
The promotion of clinician-scientists is crucial to bridge the
gap and avoid the valley of death at the early stages, as well
as the contribution of “early dialogue” and scientific advice to
define the characteristics of the patient and health care system
to which the new technological solution will be targeted to. In
fact, some highly sophisticated technological solutions such as
many “point of care” diagnostics have not been successful due
to an inadequate plan including the inexistence of companion
treatments or the insufficient knowledge of the standard of care
in different settings. However, there are examples of initiatives
that have combined experts, health care providers, and HTA
organizations and have become a reality such as the European
Union (EU) funded projects AngeLab for non-invasive prenatal
diagnosis (http://angelab-systems.eu/) or Discognosis, a Point-
of-Care diagnostic device for malaria and other tropical diseases
(http://www.discognosis.eu/).
Current initiatives to promote dialogue and funding at the
early stages include the Innovative Medicines Initiative (IMI)
that aims to facilitate and speed the access to the market
and obviously, to the patients of innovative medicines, with
an especial focus in areas where there is high unmet medical
(e.g., rare diseases) or social need (https://www.imi.europa.
eu/). IMI is a public-private joint action with the participation
of the European Union (through the European Commission)
and the European pharmaceutical industry represented by
the European Federation of Pharmaceutical Industries and
Associations (EFPIA).
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REGULATION
Market authorization or regulation has been a necessary step
that countries and health care systems have established to
build trust on the products that are marketed authorized, in
terms of safety and efficacy/performance. Developed countries
have created well-structured and demarcated processes for
market authorization, especially when they relate to health
and environment. These necessary steps have been followed
by the creation of independent institutions at the national
(Food and Drug Administration and other national bodies)
and international level (EMA) that have defined the rules
and evidence requirements to ensure that the products that
reach the market are safe and efficacious. Nevertheless, these
regulatory processes and evidence requirements for market
access are unequal for the different health technologies.
We need to bear in mind that health technology definition
embraces “any intervention developed to prevent, diagnose or
treat medical conditions; promote health; provide rehabilitation;
or organize healthcare delivery. The intervention can be a
test, device, medicine, vaccine, procedure, program or system”
(http://htaglossary.net/health+technology). Meanwhile, drug
development and market access is well-defined and regulated
in many countries in the world (at least in OECD countries),
medical devices, diagnostics, procedures, programs, or systems
do not currently follow such process. In fact, researchers and
health technology assessors have claimed for a more robust and
centralized system for medical devices in Europe (Eikermann
et al., 2013) that could enhance not only the evidence generation
necessary for decision making, but the competitiveness of
European medical devices when accessing other markets.
Another debate could be the possible evidence requirements of
procedures and programs to ensure that only those that comply
with high-quality standards are promoted to health care systems.
An open area under discussion is public health interventions.
Also here a higher level of evidence is demanded but due to the
nature of the interventions, the tools and knowledge on how to
handle evidence quality is lacking.
It is also worth noting that health care systems, services
providers, and health technologies manufacturers are demanding
an alignment of evidence requirements by regulators and
reimbursement bodies. In this sense, regulators, industry, and
HTA bodies have started common approaches to outcomes
of interest definition, stakeholders’ involvement, and possible
comparators when designing trials for market authorization
of drugs and medical devices. A pioneering initiative has
been launched by the European network of Agencies for HTA
(EUnetHTA; http://www.eunethta.eu/) as part of the Joint Action
3 funded by the EU. EUnetHTA has included a work package
(WP5) that based on previous experience in Joint Action 2
(http://www.eunethta.eu/activities/EUnetHTA_Joint_Action_2_
(2012-15)/eunethta-joint-action-2-2012--2015) promotes early-
dialogue with industry and regulators on drugs and medical
devices. This initiative tries to avoid further evidence generation
requirements on safety and efficacy and choice of comparator
when informing decision making on reimbursement. This is
especially crucial when talking about SMEs that need to be
efficient on evidence requirements and trials’ design and are
unable to afford further investments to answer HTA bodies and
health care systems.
INVESTMENT
Health care providers and organizations need to decide on
which services and technologies will be implemented into the
Health Systems, and, simultaneously, to which extent those goods
will be funded. In view of the scarce resources and the open-
ended needs that put at risk Health Systems’ sustainability, the
investment in a concrete condition or pathology impedes the
investment in other pathologies or processes, in which similar or
higher value could be generated (cost-opportunity). Unluckily,
health care providers invest in health technologies that are
not tailored to their needs or the settings in which they are
going to be applied. Likewise, the relative added value of some
health technologies at the purchasing price does not justify their
acquisition and generate tensions between health care providers,
health technology suppliers, and patients. More than desirable,
investments are not performed on the basis of priority needs
or they do not consider systems and settings characteristics
acquiring technologies that are more complex than required or
unsuited to the context where they will be provided, demanding
expensive maintenance, or very advanced capacity building to
gain the benefit of the single technology. Additionally, the
variability in practice, the irrational or inadequate use of health
technologies, the wide range of health professionals, and the lack
of required competencies to achieve the desired outcomes may
also lead to an inefficient use of investments, a spendthrift of
services, and the lack of funds vital for purchasing other more
priority resources for Health Systems. HTA could be helpful at
this stage by anticipating the possible impact and requirements
of health technologies included in different health care systems,
what it has been called “Early Awareness and Alert Systems”
(Packer et al., 2012) and by promoting evidence generation post-
marketing authorization and reimbursement decision (Varela-
Lema et al., 2012). As previously mentioned, the value of health
technologies in routine care differs from that promised in theory
and according to trials in ideal conditions. That’s why HTA
bodies, regulators, payers, health professionals, and patients are
claiming for the establishment of mechanisms that headed to the
generation of evidence in real practice what has been called “real
world data” (Schneeweiss et al., 2016). Real world data generation
supports other actions such as: “Manage Entry Agreements”
(Klemp et al., 2011), adaptive licensing for innovations market
authorization (Schneeweiss et al., 2016), and public procurement
and prices negotiation, based on comparative effectiveness,
when demonstrated value. Even legal basis had changed so
that reimbursement bodies are able to spend money into the
development of real life evidence (Germany—GKV-VSG, 2015).
DISINVESTMENT
The linear concept of health technologies life cycle was a
stop to the analysis of what happened in real practice. It
seemed to be that once decisions on reimbursement were taken,
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health technologies remained unassessed up to their disuse by
health professionals. Actually, variability in practice has been
a constant in health care systems. This variability could be
due to the personalization of the management of individual
patients or to the use of obsolete, superseded, or low-added
value practices. The analysis of variability and the identification
of low-added or no added-value practices has become a
must. Different programs have tried to systematically identify
obsolete technologies and promote disinvestment (Ibargoyen-
Roteta et al., 2009; Leggett et al., 2012; Polisena et al.,
2013). New initiatives like Choosing Wisely (USA http://
www.choosingwisely.org/; Australia http://www.choosingwisely.
org.au/home; Canada http://www.choosingwiselycanada.org/;
UK http://www.choosingwisely.co.uk/; Spain http://www.msc.
es/organizacion/sns/planCalidadSNS/cal_sscc.htm) promoted by
systems, patients, and professional societies have achieved further
attention in mass media. Notwithstanding, there is a need for
further research on sources for the identification of obsolete
technologies and their consequences in health care systems. The
systematic, comprehensive, and accountable divestment of low
added or no added value health technologies could be the basis
for budget release that enables investment in innovations that
seek greater value and better allocation of resources.
Future challenges are countless: from theoretical efficacy to
effectiveness, from traditional “one size fits all” medicine to
personalized medicine. To this evolving scenario, it must be
added the limited financial resources that will force more than
ever to select the best technology according to each concrete
system and appropriate criteria. However, this will require
stakeholders’ involvement aimed at increasing quality and value
of care (Stelfox et al., 2015).
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